Technical Analysis for ACRS - Aclaris Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
6.46 | -6.51% | -0.45 |
ACRS closed down 6.51 percent on Wednesday, January 16, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical ACRS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 16 | Oversold Stochastic | Weakness | 0.00% |
| Jan 15 | Doji - Bullish? | Reversal | -6.51% |
| Jan 15 | Stochastic Reached Oversold | Weakness | -6.51% |
| Jan 15 | Oversold Stochastic | Weakness | -6.51% |
| Jan 14 | 20 DMA Resistance | Bearish | -5.83% |
| Jan 14 | 180 Bearish Setup | Bearish Swing Setup | -5.83% |
| Jan 14 | Outside Day | Range Expansion | -5.83% |
| Jan 14 | Down 3 Days in a Row | Weakness | -5.83% |
| Jan 14 | Down 4 Days in a Row | Weakness | -5.83% |
| Jan 14 | Down 5 Days in a Row | Weakness | -5.83% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ACRS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 25.89 |
| 52 Week Low | 6.15 |
| Average Volume | 607,000 |
| 200-Day Moving Average | 14.8752 |
| 50-Day Moving Average | 8.3823 |
| 20-Day Moving Average | 7.1425 |
| 10-Day Moving Average | 7.248 |
| Average True Range | 0.4796 |
| ADX | 37.17 |
| +DI | 13.0101 |
| -DI | 30.709 |
| Chandelier Exit (Long, 3 ATRs ) | 6.7512 |
| Chandelier Exit (Short, 3 ATRs ) | 7.5888 |
| Upper Bollinger Band | 7.9293 |
| Lower Bollinger Band | 6.3557 |
| Percent B (%b) | 0.07 |
| BandWidth | 22.031502 |
| MACD Line | -0.4113 |
| MACD Signal Line | -0.4339 |
| MACD Histogram | 0.0226 |
| Fundamentals | Value |
|---|---|
| Market Cap | 172.71 Million |
| Num Shares | 26.7 Million |
| EPS | -2.03 |
| Price-to-Earnings (P/E) Ratio | -3.18 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 3.83 |
| PEG Ratio | -0.13 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.25 | ||||
| Resistance 3 (R3) | 7.32 | 7.13 | 7.12 | ||
| Resistance 2 (R2) | 7.13 | 6.93 | 7.09 | 7.07 | |
| Resistance 1 (R1) | 6.80 | 6.81 | 6.70 | 6.72 | 7.03 |
| Pivot Point | 6.61 | 6.61 | 6.56 | 6.57 | 6.61 |
| Support 1 (S1) | 6.27 | 6.40 | 6.18 | 6.20 | 5.89 |
| Support 2 (S2) | 6.08 | 6.28 | 6.04 | 5.85 | |
| Support 3 (S3) | 5.75 | 6.08 | 5.80 | ||
| Support 4 (S4) | 5.67 |
